

## Meeting Agenda

<b>Group:</b> ISPOR HTA-P&T Roundtable – North America		
<b>Date:</b> Sunday, May 20, 2018	<b>Time:</b> 8:30 am – 4:30 pm EDT	
<b>Meeting Location:</b> Baltimore Convention Center (Room: Ballroom III (Level 400)), Baltimore, MD, USA		
Time	Topic	Presenter(s)
8:30am – 8:35am	Call to Order	Brian O'Rourke Karen Worley
8:35am – 8:45am	Introduction of ISPOR HTA-P&T Roundtable Participants	All Participants
8:45am – 8:50am	ISPOR Anti-Trust Statement	Nadia Naaman
8:50am – 8:55am	Welcome by ISPOR President and CEO	Federico Augustovski, ISPOR President 2018-2019  Nancy Berg, ISPOR CEO and Executive Director
8:55am – 9:05am	Review of Agenda and Previous Meeting Minutes	Brian O'Rourke Karen Worley
9:05am – 10:30am	<b><u>Policy and Payment Options for High-Cost Therapies</u></b> <ul style="list-style-type: none"> <li>• Overview</li> <li>• Open Discussion</li> </ul>	<b><u>Moderators:</u></b> Brian O'Rourke and Steven Pearson All Participants
<b>10:30am – 10:45am</b>	<b>Coffee Break</b>	<b>All Participants</b>
10:45am – 12:15pm	<b><u>Reassessing the Value of Technologies in the Post-Market Space</u></b> <ul style="list-style-type: none"> <li>• Overview</li> <li>• Open Discussion</li> </ul>	<b><u>Moderator:</u></b> Marc Berger All Participants
<b>12:15pm – 1:15pm</b>	<b>Joint Councils Lunch (Room: Ballroom II (Level 400))</b>	<b>All Participants</b>
1:15pm – 1:25pm	<b><u>ISPOR HTA Council Updates:</u></b> <b><u>ISPOR HTA Council Working Groups</u></b> <ul style="list-style-type: none"> <li>• Overview of Good Practices for Synthesizing and Using Evidence in Health Care Decision Making</li> <li>• International Initiatives on the Assessment of the Value of Medical Technologies</li> <li>• ISPOR HTA Training Program</li> <li>• Center for Health Technology Assessment</li> </ul>	Finn Børllum Kristensen

Time	Topic	Presenter(s)
1:25pm – 1:55pm	<p><b><u>ISPOR HTA Council Updates:</u></b> <b><u>Regional HTA Developments</u></b></p> <ul style="list-style-type: none"> <li>• Asia-Pacific</li> <li>• Europe</li> <li>• Latin America</li> </ul>	Sukyeong Kim Wim Goettsch Ramiro Gilardino
1:55pm – 2:40pm	<p><b><u>Stakeholder Involvement</u></b></p> <ul style="list-style-type: none"> <li>• The stakeholders involved in the HTA process in the US and Canada. <i>(previously surveyed)</i></li> <li>• Open Discussion: <i>Who are the top 2-3 stakeholders and how are they being involved?</i></li> </ul>	<b><u>Moderators:</u></b> Brian O'Rourke and Karen Worley All Participants
2:40pm – 2:55pm	<b>Coffee Break</b>	<b>All Participants</b>
2:55pm – 4:15pm	<p><b><u>Hot Topics/Pressing Issues</u></b> <i>A tour-de-table identifying 2-3 topics/issues beyond what was discussed previously in the day. (eg, biosimilars, pricing, medical devices, methodological issues, companion diagnostics, etc)</i></p> <ul style="list-style-type: none"> <li>• Open Discussion</li> </ul>	<b><u>Moderators:</u></b> Brian O'Rourke and Karen Worley  All Participants
4:15pm – 4:30pm	<p>Next steps</p> <ul style="list-style-type: none"> <li>• Deliverable such as article based on discussion</li> <li>• Who is missing from the roundtable?</li> <li>• Key takeaway(s)</li> </ul>	Brian O'Rourke Karen Worley